Express News | ITeos Therapeutics Shares Are Trading Higher After the Company Announced the Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
Express News | ITeos Therapeutics Announces Interim Data From GALAXIES Lung-201 Study Sponsored By Partner GSK Will Be PREsented At Society For Medical Oncology Congress 2024
Express News | Iteos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 Galaxies Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
J.P. Morgan Sticks to Its Buy Rating for ITeos Therapeutics (ITOS)
ITeos Therapeutics Initiated at Overweight by Wells Fargo
Wells Fargo Initiates ITeos Therapeutics(ITOS.US) With Buy Rating, Announces Target Price $31
Express News | JP Morgan Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $24
ITeos Therapeutics Analyst Ratings
Express News | Iteos Therapeutics Inc : JP Morgan Cuts Target Price to $24 From $27
Buy Rating Affirmed for ITeos Therapeutics on Strong Financials and Promising Pipeline Updates
Express News | ITeos Therapeutics Q2 2024 GAAP EPS $(0.18) Beats $(1.04) Estimate, Pro Forma Cash And Investment Balance Of $714.4M As Of June 30, 2024 Expected To Provide Runway Through 2027
ITeos Therapeutics | 10-Q: Q2 2024 Earnings Report
ITeos Therapeutics 2Q Loss/Shr 18c >ITOS
ITeos Therapeutics 2Q Loss $7.1M >ITOS
Express News | Iteos Reports Second Quarter 2024 Financial Results and Provides Business Updates
ITeos Therapeutics Names David Feltquate Chief Medical Officer
Express News | Iteos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment
Express News | Iteos Announces First Patient Dosed in Galaxies Lung-301 Phase 3 Study, Earning $35 Million in Milestones From GSK
Sector Update: Health Care Stocks Advance in Afternoon Trading